{
  "first_published_at": "2012-05-22", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON152728", 
  "title": "Epidermal growth factor receptor (EGFR) inhibitors: serious cases of keratitis and ulcerative keratitis", 
  "tags": "{\"parsed_therapeutic\": [\"cancer\"], \"Audience:\": [\"Primary care\", \"Secondary care\"], \"Therapeutic area:\": [\"Cancer\"]}", 
  "_document_number": 113, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/adverse_icon.png", 
  "therapeutic_area": [
    "cancer"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Epidermal growth factor receptor (EGFR) inhibitors: serious cases of keratitis and ulcerative keratitis</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: May 2012</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!---->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div id=\"dsuSynopsis\" class=\"yellow\">\r\n\t\t\t\t\t\t\t\t\t<div class=\"dsuArticlePadding\">\r\n\t\t\t\t\t\t\t\t\t<span id=\"dsuSynopsisTitle\"><b>Summary</b></span>\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<br>Keratitis and ulcerative keratitis have been reported following treatment with epidermal growth factor receptor (EGFR) inhibitors for cancer, such as panitumumab (Vectibix). In rare cases, this has resulted in corneal perforation and blindness. Patients who present with acute or worsening signs and symptoms of keratitis should be referred promptly to an ophthalmology specialist. Treatment should be interrupted or discontinued if ulcerative keratitis is diagnosed.<br>\t\r\n\t\t\t\t\t\t\t\t\t</div>         \t\t\r\n\t\t\t\t\t\t\t\t\t<div id=\"dsuSynopsisCut\">\r\n\t\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>EGFR promotes cell growth in normal epithelial tissues including the skin and is expressed on a variety of tumour cells. The EGFR inhibitors, cetuximab (Erbitux), erlotinib (Tarceva&#9660;), gefitinib (Iressa&#9660;) and panitumumab (Vectibix&#9660;), are used to treat EGFR-expressing tumours.</p>\n\n<p><strong>Reports of keratitis and ulcerative keratitis</strong><br />\nThe cornea is covered with a layer of epithelium which may be damaged by treatment with EGFR inhibitors. Patients with a history of keratitis, ulcerative keratitis or severe dry eye may be particularly at risk. Serious cases of keratitis and ulcerative keratitis (corneal ulceration) have been reported with varying frequency following treatment with an EGFR inhibitor. In rare cases, this has led to corneal perforation and blindness. Ulcerative keratitis must therefore be regarded as an ophthalmological emergency.</p>\n\n<p>This issue was first identified with panitumumab (Vectibix) and a<a target=\"_blank\" href=\"/home/groups/pl-p/documents/websiteresources/con120203.pdf\"> letter sent to healthcare professionals in May 2011</a>. The risk of keratitis and severe keratitis is now considered a class effect for all EGFR inhibitors, and information for all products in this class has been updated with warnings on this risk.</p>\n\n<div class=\"dull_highlight\"><strong>Advice for healthcare professionals:</strong> \n\n<ul>\n<li>Ulcerative keratitis is an opthalmological emergency</li>\n\n<li>Patients undergoing treatment with EGFR inhibitors who present with acute or worsening signs and symptoms suggestive of keratitis such as: eye inflammation; increased lacrimation; light sensitivity; blurred vision; eye pain and/or red eye should be referred promptly to an ophthalmology specialist</li>\n\n<li>If a diagnosis of ulcerative keratitis is confirmed, treatment with the EGFR inhibitor should be interrupted or discontinued.</li>\n</ul>\n\n<p>Patients with a history of keratitis, ulcerative keratitis or severe dry eye may be particularly at risk of ocular damage with EGFR inhibitors.</p>\n</div>\n\n<p><strong>Further information:</strong></p>\n\n<p><a target=\"_blank\" href=\"/home/groups/pl-p/documents/websiteresources/con120203.pdf\">Letter to healthcare professionals on Vectibix and keratitis/ulcerative keratitis</a></p>\n\n<p>BNF section 8.1 <a target=\"_blank\" href=\"http://www.medicinescomplete.com/mc/bnf/current/4758.htm\">Cytotoxic drugs</a></p>\n\n<p>Updated product information on keratitis and ulcerative keratitis can be found in individual Summaries of Product Characteristics (see the <a target=\"_blank\" href=\"http://www.medicines.org.uk/emc/\">electronic Medicines Compendium</a>&#62;</p>\n\n<p><em>Article citation: Drug Safety Update May 2012, vol 5 issue 10: A4</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>EGFR promotes cell growth in normal epithelial tissues including the skin and is expressed on a variety of tumour cells. The EGFR inhibitors, cetuximab (Erbitux), erlotinib (Tarceva&#9660;), gefitinib (Iressa&#9660;) and panitumumab (Vectibix&#9660;), are used to treat EGFR-expressing tumours.</p>\n\n<p><strong>Reports of keratitis and ulcerative keratitis</strong><br>\nThe cornea is covered with a layer of epithelium which may be damaged by treatment with EGFR inhibitors. Patients with a history of keratitis, ulcerative keratitis or severe dry eye may be particularly at risk. Serious cases of keratitis and ulcerative keratitis (corneal ulceration) have been reported with varying frequency following treatment with an EGFR inhibitor. In rare cases, this has led to corneal perforation and blindness. Ulcerative keratitis must therefore be regarded as an ophthalmological emergency.</p>\n\n<p>This issue was first identified with panitumumab (Vectibix) and a<a target=\"_blank\" href=\"http://www.mhra.gov.uk/home/groups/pl-p/documents/websiteresources/con120203.pdf\">letter sent to healthcare professionals in May 2011</a>. The risk of keratitis and severe keratitis is now considered a class effect for all EGFR inhibitors, and information for all products in this class has been updated with warnings on this risk.</p>\n\n<div class=\"dull_highlight\"><strong>Advice for healthcare professionals:</strong> \n\n<ul>\n<li>Ulcerative keratitis is an opthalmological emergency</li>\n\n<li>Patients undergoing treatment with EGFR inhibitors who present with acute or worsening signs and symptoms suggestive of keratitis such as: eye inflammation; increased lacrimation; light sensitivity; blurred vision; eye pain and/or red eye should be referred promptly to an ophthalmology specialist</li>\n\n<li>If a diagnosis of ulcerative keratitis is confirmed, treatment with the EGFR inhibitor should be interrupted or discontinued.</li>\n</ul>\n\n<p>Patients with a history of keratitis, ulcerative keratitis or severe dry eye may be particularly at risk of ocular damage with EGFR inhibitors.</p>\n</div>\n\n<p><strong>Further information:</strong></p>\n\n<p><a target=\"_blank\" href=\"http://www.mhra.gov.uk/home/groups/pl-p/documents/websiteresources/con120203.pdf\">Letter to healthcare professionals on Vectibix and keratitis/ulcerative keratitis</a></p>\n\n<p>BNF section 8.1 <a target=\"_blank\" href=\"http://www.medicinescomplete.com/mc/bnf/current/4758.htm\">Cytotoxic drugs</a></p>\n\n<p>Updated product information on keratitis and ulcerative keratitis can be found in individual Summaries of Product Characteristics (see the <a target=\"_blank\" href=\"http://www.medicines.org.uk/emc/\">electronic Medicines Compendium</a>&gt;</p>\n\n<p><em>Article citation: Drug Safety Update May 2012, vol 5 issue 10: A4</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2012-05-01", 
  "date_last_modified": "2012-05-22", 
  "_assets": [
    {
      "content_type": "application/pdf", 
      "title": "letter sent to healthcare professionals in May 2011", 
      "assetid": 0, 
      "original_url": "http://www.mhra.gov.uk/home/groups/pl-p/documents/websiteresources/con120203.pdf", 
      "filename": "downloads/2089e08868aa8d4a41285ec7c02eb1b60aafdaf9/con120203.pdf", 
      "original_filename": "con120203.pdf"
    }, 
    {
      "content_type": "application/pdf", 
      "title": "Letter to healthcare professionals on Vectibix and keratitis/ulcerative keratitis", 
      "assetid": 1, 
      "original_url": "http://www.mhra.gov.uk/home/groups/pl-p/documents/websiteresources/con120203.pdf", 
      "filename": "downloads/2089e08868aa8d4a41285ec7c02eb1b60aafdaf9/con120203.pdf", 
      "original_filename": "con120203.pdf"
    }
  ], 
  "_item_id": 113, 
  "summary": "Keratitis and ulcerative keratitis have been reported following treatment with epidermal growth factor receptor (EGFR) inhibitors for cancer, such as panitumumab (Vectibix). In rare cases, this has resulted in corneal perforation and blindness. Patients who present with acute or worsening signs and symptoms of keratitis should be referred promptly to an ophthalmology specialist. Treatment should be interrupted or discontinued if ulcerative keratitis is diagnosed.", 
  "body": "Article date: May 2012\n\nEGFR promotes cell growth in normal epithelial tissues including the skin and is expressed on a variety of tumour cells. The EGFR inhibitors, cetuximab (Erbitux), erlotinib (Tarceva▼), gefitinib (Iressa▼) and panitumumab (Vectibix▼), are used to treat EGFR-expressing tumours.\n\nReports of keratitis and ulcerative keratitis  \nThe cornea is covered with a layer of epithelium which may be damaged by treatment with EGFR inhibitors. Patients with a history of keratitis, ulcerative keratitis or severe dry eye may be particularly at risk. Serious cases of keratitis and ulcerative keratitis (corneal ulceration) have been reported with varying frequency following treatment with an EGFR inhibitor. In rare cases, this has led to corneal perforation and blindness. Ulcerative keratitis must therefore be regarded as an ophthalmological emergency.\n\nThis issue was first identified with panitumumab (Vectibix) and a[ASSET_TAG](#ASSET0). The risk of keratitis and severe keratitis is now considered a class effect for all EGFR inhibitors, and information for all products in this class has been updated with warnings on this risk.\n\nAdvice for healthcare professionals:  \n  \n  * Ulcerative keratitis is an opthalmological emergency  \n  * Patients undergoing treatment with EGFR inhibitors who present with acute or worsening signs and symptoms suggestive of keratitis such as: eye inflammation; increased lacrimation; light sensitivity; blurred vision; eye pain and/or red eye should be referred promptly to an ophthalmology specialist  \n  * If a diagnosis of ulcerative keratitis is confirmed, treatment with the EGFR inhibitor should be interrupted or discontinued.  \n  \nPatients with a history of keratitis, ulcerative keratitis or severe dry eye may be particularly at risk of ocular damage with EGFR inhibitors.\n\nFurther information:\n\n[ASSET_TAG](#ASSET1)\n\nBNF section 8.1 [Cytotoxic drugs](http://www.medicinescomplete.com/mc/bnf/current/4758.htm)\n\nUpdated product information on keratitis and ulcerative keratitis can be found in individual Summaries of Product Characteristics (see the [electronic Medicines Compendium](http://www.medicines.org.uk/emc/)>\n\nArticle citation: Drug Safety Update May 2012, vol 5 issue 10: A4\n"
}